Ensaio de determinação de dose para avaliar a segurança e a imunogenicidade da vacina de citomegalovírus (CMV) mRNA-1647 em adultos saudáveis
Um estudo de Fase 2, randomizado, cego para observadores, controlado por placebo e de determinação de dose para avaliar a segurança e a imunogenicidade da vacina de citomegalovírus mRNA-1647 em adultos saudáveis
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
California
-
Sacramento, California, Estados Unidos, 95864
- Benchmark Research
-
-
Illinois
-
Peoria, Illinois, Estados Unidos, 61614
- Optimal Research
-
-
Kansas
-
Lenexa, Kansas, Estados Unidos, 66219
- Johnson County Clin-Trials
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40509
- Alliance for Multispecialty Research
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43213-6523
- Aventiv Research Inc
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Tekton Research Inc
-
Victoria, Texas, Estados Unidos, 77901
- Crossroads Clinical Research
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84109
- Foothill Family Clinic
-
Salt Lake City, Utah, Estados Unidos, 84121
- Foothill Family Clinic-South Clinic
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Descrição
Critério de inclusão:
- Homem ou mulher 18-40 anos de idade (Parte 1); Mulher de 18 a 40 anos (Parte 2)
- Compreende e concorda em cumprir os procedimentos do estudo e fornece consentimento informado por escrito
- De acordo com a avaliação do Investigador, está em bom estado geral de saúde e é capaz de cumprir os procedimentos do ensaio
- Índice de massa corporal (IMC) 18-35 quilogramas/metro (kg/m^2)
- As participantes do sexo feminino devem ter potencial para não engravidar ou usar métodos contraceptivos aceitáveis de pelo menos 28 dias antes da primeira vacinação e até 3 meses após a última vacinação e não estar amamentando.
- Os participantes do sexo masculino devem concordar em praticar contracepção adequada desde o momento da primeira vacinação e até 3 meses após a última vacinação.
Critério de exclusão:
- Doença aguda ou febril no dia da primeira vacinação
- Recebimento prévio de qualquer vacina CMV
- Resultados anormais de testes laboratoriais de segurança de triagem
- Diagnóstico ou condição que, no julgamento do investigador, é clinicamente instável ou pode afetar a segurança do participante, avaliação dos pontos finais de segurança, avaliação da resposta imune ou adesão aos procedimentos do estudo
- Recebeu ou planeja receber uma vacina ≤ 28 dias antes da primeira vacinação ou planeja receber uma vacina que não seja do estudo dentro de 28 dias antes ou depois de qualquer vacinação do estudo, exceto para qualquer vacina contra influenza licenciada que pode ser administrada >14 dias antes ou após qualquer vacinação em estudo. As vacinas contra a COVID-19 (independentemente do fabricante) podem ser administradas >7 dias, mas preferencialmente >14 dias antes ou depois de qualquer vacinação em estudo, com a intenção de priorizar a vacinação contra a COVID-19 sobre todas as outras considerações.
- Recebimento prévio de imunossupressores sistêmicos crônicos ou drogas imunomodificadoras
- Recebimento de imunoglobulinas intravenosas ou produtos de plasma dentro de 3 meses antes do dia da primeira vacinação do estudo
- Recebimento prévio de medicamentos na formulação de nanopartículas lipídicas (LNP) (somente participantes da Parte 1)
- Doou ≥450 mililitros (mL) de hemoderivados até 28 dias após a visita de triagem
- Participou de um ensaio clínico intervencionista nos 28 dias anteriores ao dia da inscrição
- É um membro imediato da família ou membro da família do pessoal do estudo
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
Os participantes receberão placebo correspondente à dose da vacina mRNA-1647 por injeção IM no dia 1, dia 56 e dia 168.
|
Injeção de cloreto de sódio a 0,9% (solução salina normal)
|
|
Experimental: mRNA-1647 Dose Nível A
Os participantes receberão a vacina mRNA-1647 na Dose Nível A por injeção intramuscular (IM) no Dia 1, Dia 56 e Dia 168.
|
Produto liofilizado que é reconstituído com soro fisiológico e depois diluído com um diluente especial para atingir a concentração desejada
|
|
Experimental: Nível de dose B de mRNA-1647
Os participantes receberão a vacina mRNA-1647 no nível de dose B por injeção IM no Dia 1, Dia 56 e Dia 168.
|
Produto liofilizado que é reconstituído com soro fisiológico e depois diluído com um diluente especial para atingir a concentração desejada
|
|
Experimental: mRNA-1647 Dose Nível C
Os participantes receberão a vacina mRNA-1647 na Dose Nível C por injeção IM no Dia 1, Dia 56 e Dia 168.
|
Produto liofilizado que é reconstituído com soro fisiológico e depois diluído com um diluente especial para atingir a concentração desejada
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Prazo: Up to Day 175 (7 days following last dose administration)
|
Solicited ARs were selected signs and symptoms occurring after vaccination administration during a specified post-vaccination follow-up period.
The occurrence and intensity of the selected signs and symptoms was actively solicited from the participant during a specified post-vaccination follow-up period (day of vaccination and 6 subsequent days), using a predefined checklist in the electronic diary.
The following local ARs were solicited: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the vaccination arm.
The following systemic ARs were solicited: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, fever, and chills.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
|
Up to Day 175 (7 days following last dose administration)
|
|
Number of Participants With Unsolicited Adverse Events (AEs)
Prazo: Up to Day 196 (28 days following last dose administration)
|
An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section."
|
Up to Day 196 (28 days following last dose administration)
|
|
Number of Participants With Medically Attended Adverse Events (MAAEs)
Prazo: Up to Day 336 (6 months following last dose administration)
|
An MAAE is an AE that lead to a visit to a healthcare practitioner (HCP).
This would include visits to study clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up), and visits to HCPs external to the clinical site (for example, urgent care, primary care physician).
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section."
|
Up to Day 336 (6 months following last dose administration)
|
|
Number of Participants With Serious Adverse Events (SAEs)
Prazo: Up to Day 504 (1 year following last dose administration)
|
An SAE was defined as any untoward medical occurrence that, in the view of either the Investigator or the Sponsor, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event.
A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section."
|
Up to Day 504 (1 year following last dose administration)
|
|
Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection
Prazo: Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity (AMI) analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
Results are reported as fold dilution (titer).
GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
Geometric Mean Ratio (GMR) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
The GMR measures the changes in immunogenicity titers within participants.
Results are reported as a ratio (post-baseline/baseline titers).
GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases in Neutralizing Antibodies (nAb) Over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
A ≥z-fold increase from baseline at participant level was defined as a ≥z * the lower limit of quantification (LLOQ) for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ.
LLOQ=16.
Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline.
95% CI for percentage is calculated using the Clopper-Pearson method.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
GMT of Anti-Glycoprotein B (gB)-Specific Immunoglobulin G (IgG) and Anti-Pentamer-specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) of Post-Baseline/Baseline Titers
Prazo: Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits.
Serological assessment for anti-gB-specific IgG and anti-pentameric gH/gL/UL128/UL130/UL131A glycoprotein complex (Pentamer)-specific IgG binding was measured with ELISA.
The GMT measures the level of inhibition of anti-gB-specific IgG (anti-gB) and anti-Pentamer-specific IgG (anti-Pentamer) against cytomegalovirus.
Results are reported as fold dilution (titer).
GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
GMR of Anti-gB-specific IgG and Anti-Pentamer-specific IgG as Measured by ELISA of Post-Baseline/Baseline Titers
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits.
Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA.
The GMR measures the changes in immunogenicity titers within participants.
Results are reported as a ratio (post-baseline/baseline titers).
GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Number Analyzed = participants who were evaluable at specified timepoints.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
GMT of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group
Prazo: Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
Results are reported as fold dilution (titer).
GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
GMR of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
The GMR measures the changes in immunogenicity titers within participants.
Results are reported as a ratio (post-baseline/baseline titers).
GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection in the CMV-Seropositive and CMV-Seronegative Groups
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits.
Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay.
A ≥z-fold increase from baseline at participant level was defined as a ≥z * the LLOQ for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ.
LLOQ=16.
Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline.
95% CI for percentage is calculated using the Clopper-Pearson method.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
GMT of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups
Prazo: Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits.
Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA.
Results are reported as fold dilution (titer).
GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
|
GMR of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups
Prazo: Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits.
Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA.
The GMR measures the changes in immunogenicity titers within participants.
Results are reported as a ratio (post-baseline/baseline titers).
GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
|
Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- mRNA-1647-P202
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .